Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ErbB Receptors | 6 | 2014 | 516 | 1.590 |
Why?
|
| src Homology Domains | 6 | 2017 | 46 | 1.500 |
Why?
|
| Protein Array Analysis | 6 | 2017 | 53 | 0.940 |
Why?
|
| Proteins | 4 | 2017 | 804 | 0.930 |
Why?
|
| Protein Interaction Mapping | 3 | 2017 | 79 | 0.870 |
Why?
|
| Signal Transduction | 8 | 2015 | 3620 | 0.780 |
Why?
|
| Blotting, Western | 2 | 2017 | 780 | 0.720 |
Why?
|
| Proteome | 4 | 2015 | 163 | 0.710 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 86 | 0.490 |
Why?
|
| Fluorescence Polarization | 2 | 2014 | 12 | 0.480 |
Why?
|
| Quantitative Trait Loci | 3 | 2014 | 663 | 0.450 |
Why?
|
| Proteomics | 3 | 2017 | 279 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.410 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 125 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 199 | 0.370 |
Why?
|
| Phenylethyl Alcohol | 1 | 2012 | 1 | 0.370 |
Why?
|
| Caffeic Acids | 1 | 2012 | 5 | 0.370 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.360 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.360 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 191 | 0.330 |
Why?
|
| Phosphorylation | 5 | 2014 | 1145 | 0.310 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1790 | 0.290 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2063 | 0.290 |
Why?
|
| Carcinoma | 1 | 2012 | 440 | 0.290 |
Why?
|
| Transcription Factors | 3 | 2014 | 1717 | 0.260 |
Why?
|
| Protein Binding | 5 | 2014 | 1554 | 0.220 |
Why?
|
| Cell Line, Tumor | 6 | 2017 | 2888 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1836 | 0.160 |
Why?
|
| Phosphotyrosine | 2 | 2014 | 31 | 0.160 |
Why?
|
| Systems Biology | 2 | 2011 | 51 | 0.160 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 2 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 75 | 0.150 |
Why?
|
| Phosphopeptides | 2 | 2012 | 11 | 0.150 |
Why?
|
| Surface Plasmon Resonance | 2 | 2012 | 48 | 0.150 |
Why?
|
| Nitrogen Fixation | 2 | 1989 | 8 | 0.140 |
Why?
|
| Rhodopseudomonas | 2 | 1989 | 40 | 0.140 |
Why?
|
| Genetic Variation | 3 | 2014 | 1445 | 0.140 |
Why?
|
| Genes, Bacterial | 2 | 1989 | 150 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 199 | 0.140 |
Why?
|
| Cisplatin | 2 | 2017 | 578 | 0.130 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 1850 | 0.120 |
Why?
|
| Humans | 16 | 2020 | 98080 | 0.120 |
Why?
|
| Cell Line | 2 | 2014 | 2483 | 0.120 |
Why?
|
| Base Sequence | 4 | 2014 | 2222 | 0.110 |
Why?
|
| Computational Biology | 2 | 2011 | 613 | 0.110 |
Why?
|
| Amino Acid Sequence | 5 | 2010 | 2005 | 0.110 |
Why?
|
| Genome, Human | 3 | 2014 | 832 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2015 | 264 | 0.100 |
Why?
|
| Tyrosine | 1 | 2014 | 135 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 3272 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 261 | 0.100 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 106 | 0.100 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 1061 | 0.100 |
Why?
|
| Animals | 9 | 2017 | 28894 | 0.100 |
Why?
|
| Mice, Nude | 2 | 2012 | 830 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 388 | 0.100 |
Why?
|
| Genotype | 2 | 2014 | 1888 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 321 | 0.090 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 96 | 0.090 |
Why?
|
| Antibodies | 1 | 2014 | 348 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 564 | 0.090 |
Why?
|
| Cytotoxins | 1 | 2012 | 18 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 312 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2014 | 472 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 551 | 0.090 |
Why?
|
| Cell Physiological Phenomena | 1 | 2011 | 24 | 0.090 |
Why?
|
| Transcriptome | 2 | 2014 | 820 | 0.080 |
Why?
|
| Binding Sites | 1 | 2014 | 1159 | 0.080 |
Why?
|
| Viruses | 1 | 2011 | 64 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 1989 | 236 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2014 | 1005 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 2023 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 911 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2012 | 529 | 0.080 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2010 | 2 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 556 | 0.080 |
Why?
|
| Gene Expression | 1 | 2014 | 1320 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 1018 | 0.080 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 20 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 88 | 0.080 |
Why?
|
| Sirolimus | 1 | 2011 | 182 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 1110 | 0.080 |
Why?
|
| Methionine | 1 | 2009 | 64 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 2373 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1565 | 0.070 |
Why?
|
| Indoles | 1 | 2011 | 334 | 0.070 |
Why?
|
| Equipment Design | 1 | 2010 | 425 | 0.070 |
Why?
|
| Receptor, ErbB-4 | 1 | 2008 | 5 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1255 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2011 | 552 | 0.060 |
Why?
|
| Software | 2 | 2015 | 693 | 0.060 |
Why?
|
| Algorithms | 1 | 2015 | 2002 | 0.060 |
Why?
|
| Peptides | 1 | 2010 | 669 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2009 | 489 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 2896 | 0.060 |
Why?
|
| Breast | 1 | 2008 | 315 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 481 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2558 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1945 | 0.060 |
Why?
|
| Heart | 1 | 2008 | 527 | 0.060 |
Why?
|
| Mice | 4 | 2012 | 12698 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2005 | 480 | 0.050 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 6 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1105 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2017 | 317 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 731 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1088 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1416 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2784 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 89 | 0.050 |
Why?
|
| Prognosis | 1 | 2008 | 4116 | 0.040 |
Why?
|
| Genomics | 1 | 2005 | 898 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 161 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 1764 | 0.040 |
Why?
|
| Tribolium | 1 | 1997 | 10 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 2430 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 211 | 0.030 |
Why?
|
| Hybridization, Genetic | 1 | 1997 | 107 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 822 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 502 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 2638 | 0.030 |
Why?
|
| Apoptosis | 2 | 2014 | 1752 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 696 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 135 | 0.030 |
Why?
|
| Male | 3 | 2020 | 47076 | 0.030 |
Why?
|
| HapMap Project | 1 | 2014 | 47 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2014 | 483 | 0.020 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Interferons | 1 | 2011 | 114 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 122 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 111 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 399 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| RNA, Transfer, Met | 1 | 2009 | 6 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 212 | 0.020 |
Why?
|
| Genetic Code | 1 | 2009 | 24 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 46 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 353 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2010 | 403 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1028 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 220 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2009 | 87 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 401 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 356 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 374 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 1014 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2009 | 340 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 523 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 486 | 0.020 |
Why?
|
| Female | 4 | 2020 | 51536 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1987 | 47 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 525 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 640 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1391 | 0.010 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2004 | 10 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3598 | 0.010 |
Why?
|
| Culture Media | 1 | 2004 | 138 | 0.010 |
Why?
|
| Heparin | 1 | 2004 | 182 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 557 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2004 | 572 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 29428 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 29539 | 0.010 |
Why?
|
| Sexual Behavior, Animal | 1 | 1997 | 97 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1807 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1987 | 157 | 0.000 |
Why?
|
| Species Specificity | 1 | 1987 | 690 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1987 | 479 | 0.000 |
Why?
|
| DNA | 1 | 1987 | 1274 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 4071 | 0.000 |
Why?
|